207 related articles for article (PubMed ID: 29443503)
1. Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies.
van Rosmalen M; Ni Y; Vervoort DFM; Arts R; Ludwig SKJ; Merkx M
Anal Chem; 2018 Mar; 90(5):3592-3599. PubMed ID: 29443503
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic Bioluminescent Sensor Proteins for Direct Detection of Antibodies and Small Molecules in Solution.
Arts R; Ludwig SKJ; van Gerven BCB; Estirado EM; Milroy LG; Merkx M
ACS Sens; 2017 Nov; 2(11):1730-1736. PubMed ID: 29037030
[TBL] [Abstract][Full Text] [Related]
3. Bioluminescence Goes Dark: Boosting the Performance of Bioluminescent Sensor Proteins Using Complementation Inhibitors.
Gräwe A; Merkx M
ACS Sens; 2022 Dec; 7(12):3800-3808. PubMed ID: 36450135
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits.
Truffot A; Jourdil JF; Seitz-Polski B; Malvezzi P; Brglez V; Stanke-Labesque F; Gautier-Veyret E
Clin Biochem; 2021 Jan; 87():60-66. PubMed ID: 33096054
[TBL] [Abstract][Full Text] [Related]
5. Detection of Antibodies in Blood Plasma Using Bioluminescent Sensor Proteins and a Smartphone.
Arts R; den Hartog I; Zijlema SE; Thijssen V; van der Beelen SH; Merkx M
Anal Chem; 2016 Apr; 88(8):4525-32. PubMed ID: 27018236
[TBL] [Abstract][Full Text] [Related]
6. A Genetically Encoded Bioluminescent System for Fast and Highly Sensitive Detection of Antibodies with a Bright Green Fluorescent Protein.
Deng M; Yuan J; Yang H; Wu X; Wei X; Du Y; Wong G; Tao Y; Liu G; Jin Z; Chu J
ACS Nano; 2021 Nov; 15(11):17602-17612. PubMed ID: 34726889
[TBL] [Abstract][Full Text] [Related]
7. Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor.
AlRabiah H; Hamidaddin MA; Darwish IA
Talanta; 2019 Jan; 192():331-338. PubMed ID: 30348399
[TBL] [Abstract][Full Text] [Related]
8. Ratiometric Bioluminescent Sensor Proteins Based on Intramolecular Split Luciferase Complementation.
Ni Y; Arts R; Merkx M
ACS Sens; 2019 Jan; 4(1):20-25. PubMed ID: 30525479
[TBL] [Abstract][Full Text] [Related]
9. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
10. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
[TBL] [Abstract][Full Text] [Related]
11. Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies.
Campbell E; Adamson H; Kohl D; Tiede C; Wälti C; Tomlinson DC; Jeuken LJC
Biosens Bioelectron; 2023 Oct; 237():115488. PubMed ID: 37419072
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
13. [Principal therapeutic uses of monoclonal antibodies in oncology].
Penault-Llorca F; Etessami A; Bourhis J
Cancer Radiother; 2002 Nov; 6 Suppl 1():24s-28s. PubMed ID: 12587379
[TBL] [Abstract][Full Text] [Related]
14. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
15. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
Front Immunol; 2020; 11():609941. PubMed ID: 33505398
[TBL] [Abstract][Full Text] [Related]
16. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
17. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
18. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
19. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
